Clinical Trials · NCT00508287
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 36
- Start date
- Aug 2007
- Locations
- 3 sites, United States
- Primary endpoint
- Safety: incidence of adverse events